Could Eli Lilly and Precision BioSciences Make Breakthroughs for DMD?

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Nov 20, 2020 at 11:12 AM.

  1. #1 cafead, Nov 20, 2020 at 11:12 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,973
    Likes Received:
    3
    via Eli Lilly and Company and Precision BioSciences, Inc. announced today that they have entered a research collaboration and exclusive license agreement to use Precision’s ARCUS genome editing platform to research and develop potential in vivo therapies for a series of genetic disorders. Specifically, the companies will be focusing on Duchenne muscular dystrophy (DMD), along with two other undisclosed gene targets. ARCUS will give them the opportunity to make a variety of efficient edits, enabling a range of therapeutic editing.

    article source
     
    Quote

Reply to Thread